-General Experimental Solvents and reagents
All solvents were purchased from commercial sources and used without purification (HPLC or analytical grade). Anhydrous solvent was obtained from a Pure Solv™ Solvent Purification System. Standard vacuum line techniques were used and glassware was oven dried prior to use. Organic solvents were dried during workup using anhydrous Na2SO4. All calcium catalysed reactions where done without the need for anhydrous or air free conditions.
Purification and chromatography
Thin Layer Chromatography (TLC) was carried out using aluminium plates coated with 60 F254 silica gel. Plates were visualised using UV light (254 or 365 nm) or staining with 1% aq. KMnO4. Normalphase silica gel chromatography was carried out using either a Biotage Isolera One flash column chromatography system (LPLC) or traditional flash column chromatography using Geduran® Silica gel 60, 40-63 microns RE.
Characterisation
Infrared spectroscopy was carried out with a Nicolet® 380 FT/IR -Fourier Transform Infrared Spectrometer. Only the most significant frequencies have been considered during the characterization and selected absorption maxima (max) recorded in wavenumbers (cm -1 ). NMR spectra were recorded using a JEOL® ECS-400 MHz spectrometer using the deuterated solvent stated. Chemical shifts (δ) quoted in parts per million (ppm) and referenced to the residual solvent peak. Multiplicities are denoted as s-singlet, d-doublet, t-triplet, q-quartet and quin-quintet and derivatives thereof (br denotes a broad resonance peak). Coupling constants recorded as Hz and round to the nearest 0.1 Hz. High Resolution Mass Spectrometry (HRMS) was recorded using an Agilent Technologies® 6540 Ultra-High-Definition (UHD) AccurateMass equipped with a time of flight (Q-TOF) analyzer and the samples were ionized by ESI techniques and introduced through a high pressure liquid chromatography (HPLC) model Agilent Technologies® 1260 Infinity Quaternary LC system. Compound names were generated using ChemBioDraw Ultra v14 systematic naming
-General Procedures
General procedure A -Synthesis of hydroxyisoindolinones via Grignard addition To a flame dried round bottomed flask purged with argon was added the corresponding phthalimide (1 equiv.) and anhydrous DCM (0.25 M). The suspension was cooled to 0 o C and the required Grignard reagent (3 equiv) was added dropwise over 5 minutes. The resulting solution was stirred at 0 o C for 10 minutes before being allowed to warm to room temperature over 2 hours. Once TLC analysis indicated conversion to the product, the reaction was quenched with sat. aq. NH4Cl, extracted with Et2O (3 x 25 mL), the combined organic layers washed with water, brine, dried with Na2SO4, filtered and concentrated. Flask column chromatography afforded the desired compounds General procedure B -Synthesis of hydroxyisoindolinones via organolithium addition To a flame dried round bottomed flask purged with argon was added the corresponding (hetero)aryl bromide (3 equiv.) and anhydrous THF (0.25 M). The solution was cooled to -78 o C and nBuLi (2 equiv rel. to bromide, 2.5 M in hexanes) was added dropwise. The resulting solution was stirred at -78 o C for 2 hours. Phthalimide was then added in one portion and the reaction was stirred at the stated temperature and time. The reaction was quenched with sat. aq. NH4Cl, extracted with EtOAc (3 x 25 mL), the combined organic layers washed with water, brine, dried with Na2SO4, filtered and concentrated. Flask column chromatography afforded the desired compounds General procedure C -Calcium catalysed allylation To a 22mL vial equipped with a magnetic stirrer bar was added hydroxyisoindolinone, 1 mol% Ca(NTf2)2 , 1 mol% nBu4NPF6, followed by 1,2-DCE (1.5 mL), and the corresponding allyl silane (1.5 equiv.). The vial was sealed with a Teflon cap and the mixture stirred at 80 o C until TLC analysis indicated complete conversion to the product (approx. 30 mins). The mixture was concentrated and purified by flash column chromatography affording the desired compound.
Stock solutions were used for difficult to measure quantities. A 1M solution of both Ca(NTf2)2 and nBu4NPF6 in THF was prepared and the desired quantities taken via syringe and placed in the reaction vessel. The solvent was then removed under vacuum before the addition of the other reagents.
NB It was noted during the course of this study that the catalytic efficiency of the calcium salt slowly degrades over time. To ensure optimum activity, the commercial calcium salt should be thoroughly dried at 100 o C under vacuum for 12 hours before use and stored in a dessicator.
-Synthesis of hydroxyindolinones
All hydroxyindolinones (1a,  1 1b,  2 1c,  3 1d,  1 1e,  1 1f,  1 1g,  1 1h,  4 1i,   5   1j,   6   1l,   7   1m,   8   1n,   9 1o, 10 1p,
11
) were synthesised via known methods (GP1 and GP2). All spectral data were in accordance to previously described.
-Calcium catalyzed allylation reactions 3-allyl-3-phenylisoindolin-1-one (2a)
The title compound was prepared according to general procedure C, from 1a (250 mg, 1.11 mmol) using Ca(NTf2)2 (6.7 mg, 0.011 mmol), nBu4PF6 (4.3 mg, 0.011 mmol) and allyltrimethylsilane (190 mg, 1.67 mmol) in DCE (2.5 mL). Following conversion to the product and column chromatography (1: 
3-allyl-3-(4-methoxyphenyl)isoindolin-1-one (2d)
The title compound was prepared according to general procedure C, from 1d (102 mg, 0.4 mmol) using Ca(NTf2)2 (2 mg, 0.004 mmol), nBu4PF6 (1.5 mg, 0.004 mmol) and allyltrimethylsilane (68 mg, 0.6 mmol) in DCE (2 mL). Following conversion to the product and column chromatography 
3-allyl-3-(2-methoxyphenyl)isoindolin-1-one (2e)
The title compound was prepared according to general procedure C, from 1e (211 mg, 0.87 mmol) using Ca(NTf2)2 (5 mg, 0.009 mmol), nBu4PF6 (3 mg, 0.009 mmol) and allyltrimethylsilane (149 mg, 1.3 mmol) in DCE (2 mL). Following conversion to the product and column chromatography (1:1 EtOAc:cyclohexane) afforded 2e as a pale yellow oil which solidified upon standing (220 mg, 91%) RF 
3-allyl-3-(3,5-bis(trifluoromethyl)phenyl)isoindolin-1-one (2f)
The title compound was prepared according to general procedure C, from 1e (117 mg, 0.324 mmol) using Ca (NTf2)2 (2 mg 
3-allyl-3-(4-chloro-2-methylphenyl)isoindolin-1-one (2g)
The title compound was prepared according to general procedure C, from 1G (120 mg, 0.432 mmol) using Ca(NTf2)2 (2.5 mg, 0.004 mmol), nBu4PF6 (1.7 mg, 0.004 mmol) and allyltrimethylsilane (74 mg, 0.65 mmol) in DCE (2 mL). Following conversion to the product and column chromatography (1: 
3-allyl-3-(4-morpholinophenyl)isoindolin-1-one (2h)
The title compound was prepared according to general procedure C, from 1h (120 mg, 0.387 mmol) using Ca(NTf2)2 (2.3 mg, 0.004 mmol), nBu4PF6 (1.5 mg, 0.004 mmol) and allyltrimethylsilane (66 mg, 0.58 mmol) in DCE (2 mL). Following conversion to the product and column chromatography (1:1 EtOAc:cyclohexane) afforded 2h as a pale yellow solid (97 mg, 75%) RF 
3-allyl-3-(furan-2-yl)isoindolin-1-one (2i)
The title compound was prepared according to general procedure C, from 1i (150 mg, 0.698 mmol) using Ca(NTf2)2 (4 mg, 0.007 mmol), nBu4PF6 (2.7 mg, 0.007 mmol) and allyltrimethylsilane (119 mg, 1.05 mmol) in DCE (2 mL). Following conversion to the product and column chromatography 
3-allyl-3-(thiophen-2-yl)isoindolin-1-one (2j)
The title compound was prepared according to general procedure C, from 1j (50 mg, 0.217 mmol) using Ca(NTf2)2 (1.3 mg, 0.002 mmol), nBu4PF6 (0.8 mg, 0.002 mmol) and allyltrimethylsilane (37 mg, 0.325 mmol) in DCE (1 mL). Following conversion to the product and column chromatography (1:1 EtOAc:cyclohexane) afforded 2j as a yellow oil (48 mg, 88%) RF 
3-allyl-3-(benzo[d][1,3]dioxol-5-yl)isoindolin-1-one (2k)
The title compound was prepared according to general procedure C, from 1k (71 mg, 0.264 mmol) using Ca(NTf2)2 (1.6 mg, 0.003 mmol), nBu4PF6 (1 mg, 0.003 mmol) and allyltrimethylsilane (45 mg, 0.396 mmol) in DCE (1 mL). Following conversion to the product and column chromatography (1: 
3-allyl-2-benzylisoindolin-1-one (2l)
The title compound was prepared according to general procedure C, from 1l (71 mg, 0.264 mmol) using Ca (NTf2) The title compound was prepared according to general procedure C, from 1m (100 mg, 0.317 mmol) using Ca(NTf2)2 (1.9 mg, 0.003 mmol), nBu4PF6 (1.2 mg, 0.003 mmol) and allyltrimethylsilane (54 mg, 0.476 mmol) in DCE (2 mL). Following conversion to the product and column chromatography (10% EtOAc:cyclohexane) afforded 2m as a colourless oil which solidified upon standing (102 mg, 95%) 
3-allyl-2-benzyl-3-(4-chlorophenyl)isoindolin-1-one (2n)
The title compound was prepared according to general procedure C, from 1n (100 mg, 0.287 mmol) using Ca(NTf2)2 (1.7 mg, 0.003 mmol), nBu4PF6 (1.1 mg, 0.003 mmol) and allyltrimethylsilane (49 mg, 0.429 mmol) in DCE (2 mL). Following conversion to the product and column chromatography (10% EtOAc:cyclohexane) afforded 2n as a colourless oil which solidified upon standing (102 mg, 95%) 
3-allyl-3-(4-chlorophenyl)-2-methylisoindolin-1-one (2o)
The title compound was prepared according to general procedure C, from 1o (100 mg, 0.366 mmol) using Ca (NTf2) 
2,3-diallyl-3-phenylisoindolin-1-one (2p)
The title compound was prepared according to general procedure C, from 1p (207 mg, 0.781 mmol) using Ca(NTf2)2 (5 mg, 0.008 mmol), nBu4PF6 (3 mg, 0.008 mmol) and allyltrimethylsilane (134 mg, 1.172 mmol) in DCE (2 mL). Following conversion to the product and column chromatography (10% EtOAc:cyclohexane) afforded 2n as a colourless oil which solidified upon standing (207 mg, 92%) RF (5% EtOAc/CycHex) = 0.39 IR ʋmax (cm 
3-(2-methylallyl)-3-phenylisoindolin-1-one (3a)
The title compound was prepared according to general procedure C, from 1a (110 mg, 0.489 mmol) using Ca(NTf2)2 (2.9 mg, 0.005 mmol), nBu4PF6 (1.9 mg, 0.005 mmol) and methylallyltrimethylsilane (94 mg, 0.735 mmol) in DCE (2 mL). Following conversion to the product and column chromatography (1:1 EtOAc:cyclohexane) afforded 3a as a colourless oil which solidified upon standing (118 mg, 92%) RF 
3-(2-methylallyl)-3-(4-(trifluoromethyl)phenyl)isoindolin-1-one (3b)
The title compound was prepared according to general procedure C, from 1b (163 mg, 0.556 mmol) using Ca (NTf2) 
3-(2-methoxyphenyl)-3-(2-methylallyl)isoindolin-1-one (3c)
The title compound was prepared according to general procedure C, from 1e (164 mg, 0.675 mmol) using Ca(NTf2)2 (4 mg, 0.007 mmol), nBu4PF6 (2.5 mg, 0.006 mmol) and methylallyltrimethylsilane (129 mg, 1.02 mmol) in DCE (2 mL). Following conversion to the product and column chromatography (1:1 EtOAc:cyclohexane) afforded 3c as a pale yellow oil which solidified upon standing (172 mg, 87%) RF 
3-(3,5-bis(trifluoromethyl)phenyl)-3-(2-methylallyl)isoindolin-1-one (3d)
The title compound was prepared according to general procedure C, from 1f (71 mg, 0.197 mmol) using Ca(NTf2)2 (1 mg, 0.002 mmol), nBu4PF6 (0.7 mg, 0.002 mmol) and methylallyltrimethylsilane (37 mg, 0.296 mmol) in DCE (1 mL). Following conversion to the product and column chromatography 
3-(2-(4-bromophenyl)allyl)-3-phenylisoindolin-1-one (3e)
The title compound was prepared according to general procedure C, from 1a (43 mg, 0.191 mmol) using Ca(NTf2)2 (1 mg, 0.002 mmol), nBu4PF6 (0.7 mg, 0.002 mmol) and (2-(4-bromophenyl)allyl)trimethylsilane 12 (77 mg, 0.287 mmol) in DCE (1 mL). Following conversion to the product and column chromatography (25% EtOAc:cyclohexane) afforded 3e as a colourless oil which solidified upon standing (70 mg, 91%) RF 3-(2-(4-bromophenyl)allyl)-3-(4-chlorophenyl)isoindolin-1-one (3f) The title compound was prepared according to general procedure C, from 1a (50 mg, 0.191 mmol) using Ca(NTf2)2 (1 mg, 0.002 mmol), nBu4PF6 (0.7 mg, 0.002 mmol) and (2-(4-bromophenyl)allyl)trimethylsilane 12 
3-(3,5-bis(trifluoromethyl)phenyl)-3-(2-(4-bromophenyl)allyl)isoindolin-1-one (3g)
The title compound was prepared according to general procedure C, from 1a (69 mg, 0.191 mmol) using Ca(NTf2)2 (1 mg, 0.002 mmol), nBu4PF6 (0.7 mg, 0.002 mmol) and (2-(4-bromophenyl)allyl)trimethylsilane 12 (77 mg, 0.287 mmol) in DCE (1 mL). Following conversion to the product and column chromatography (25% EtOAc:cyclohexane) afforded 3g as a pale yellow oil which solidified upon standing (83 mg, 80%) 
3-(2-(4-bromophenyl)allyl)-3-(2-methoxyphenyl)isoindolin-1-one (3h)
The title compound was prepared according to general procedure C, from 1a (49 mg, 0.191 mmol) using Ca(NTf2)2 (1 mg, 0.002 mmol), nBu4PF6 (0.7 mg, 0.002 mmol) and (2-(4-bromophenyl)allyl)trimethylsilane 12 (77 mg, 0.287 mmol) in DCE (1 mL). Following conversion to the product and column chromatography (25% EtOAc:cyclohexane) afforded 3g as a pale yellow oil which solidified upon standing (71 mg, 86%) RF 
3-allyl-3-(4-(furan-3-yl)phenyl)-2-methylisoindolin-1-one (5)
To a 22 mL vial equipped with a magnetic stirrer was added 2o (50mg, 0.168 mmol) and SPhos Pd G3 (7mg, 0.008 mmol) and 3-Furanylboronic acid (28mg, 0.252 mmol) and flask purged with argon. Anhydrous and degassed 1,4-dioxane (1mL) and aq. K3P04 (1.6mL, 0.797 mmol, 0.5M, degassed) was added. The vial was capped with a Teflon cap and stirred at 100 o C for 16 hours. The mixture was passed through a plug of celite, washed with Et2o, and the organic washing concentrated in vacuo. The residue was purified by flash column chromatography (10% EtOAc in hex) to afford the desired compound as a pale yellow solid (48mg, 87%) To a 22mL vial was added 2p (92 mg, 0.346 mmol), Ca(NTf2)2 (2 mg, 0.003 mmol), nBu4PF6 (1.3 mg, 0.003 mmol) followed by the addition of allyltrimethylsilane (43 mg, 0.381 mmol) in DCE (2 mL). The mixture was stirred at 80 o C for 1 hour, and TLC analysis indicated complete conversion to the desired product. The mixture was concentrated in vacuo to afford a pale yellow residue which was redissolved in anhydrous DCM (11.5 mL, 0.03M) followed by the addition of Grubb's 1 st generation (3 mg, 0.003 mmol) and the resulting mixture stirred at 50 o C for 12 hours. The mixture was then concentrated to afford a dark brown residue which was purified by flash column chromatography (0-5% EtOAc in hexane) to afford the title compound as a colourless oil (70mg, 78% 
